Hjem
Per Eystein Lønnings bilde

Per Eystein Lønning

Professor
  • E-postPer.Lonning@uib.no
  • Telefon+47 55 97 20 10+47 55 97 20 27
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning har arbeidet sammenhengende innenfor kreftbehandling og forskning fra 1982. Han har fra 1990 vært overlege ved Kreftavdelingen, Haukeland Sykehus, og fra 1992 Professor ved Universitetet i Bergen.  Han leder Brystkreftgruppen ved Mohn kreftforskningslaboratorium. Gruppen, som i alt teller vel 20 medlemmer, arbeider hovedsakelig med brystkreft men og med andre kreftsykdommer, som tykktarmskreft og føflekkkreft. Gruppen består av forskere i Mohn Kreftforskningslaboratorium samt leger ved Kreftavdelingen, der flere i likhet med Lønning arbeider både med pasientbehandling og laboratorie-forskning. Lønning har arbeidet både med virkningsmekanismene for hormonell behandling samt cellegift ved brystkreft, og i tillegg arbeidet med kreftrisiko-faktorer. Hovedfeltet nå er mekanismer for resistens mot cellegift. 

Vitenskapelig artikkel
  • Flågeng, Marianne Hauglid; Knappskog, Stian; Haynes, Ben P.; Lønning, Per Eystein; Mellgren, Gunnar. 2013. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLOS ONE. 12 sider.
  • Berge, Elisabet Ognedal; Huun, Johanna; Lillehaug, Johan R.; Lønning, Per Eystein; Knappskog, Stian. 2013. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 2790-2797.
  • Tahiri, Andliena; Røe, Kathrine; Ree, Anne Hansen; de Wijn, Rik; Risberg, Karianne; Busch, Christer; Lønning, Per Eystein; Kristensen, Vessela N.; Geisler, Jürgen. 2013. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLOS ONE.
  • Arnes, Jarle; Stefansson, Ingunn Marie; Straume, Oddbjørn; Baak, Jan P.A.; Lønning, Per Eystein; Foulkes, William D.; Akslen, Lars A. 2012. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment. 501-510.
  • Knappskog, Stian; Trovik, Jone; Marcickiewicz, Janusz; Tingulstad, Solveig; Staff, Anne Cathrine; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Salvesen, Helga Birgitte; Lønning, Per Eystein. 2012. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European Journal of Cancer. 1988-1996.
  • Cao, Maria Dung; Giskeødegård, Guro F.; Bathen, Tone Frost; Sitter, Beathe; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer. 11 sider.
  • Cao, Maria Dung; Sitter, Beathe; Bathen, Tone Frost; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2012. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR in Biomedicine. 369-378.
  • Lønning, Per Eystein. 2012. Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic advances in medical oncology.
  • Mathiesen, Randi Margit Ruud; Borgen, Elin; Renolen, Anne; Løkkevik, Erik; Nesland, Jahn M; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Kvalheim, Gunnar; Lønning, Per Eystein; Naume, Bjørn. 2012. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research. 13 sider.
  • Knappskog, Stian; Gansmo, Liv Beathe; Romundstad, Pål Richard; Bjørnslett, Merete Pauline; Trovik, Jone; Sommerfelt-Pettersen, Jan; Løkkevik, Erik; Tollenaar, Rob A.E.M.; Seynaeve, Caroline; Devilee, Peter; Salvesen, Helga Birgitte; Dørum, Anne; Hveem, Kristian; Vatten, Lars Johan; Lønning, Per Eystein. 2012. MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. PLOS ONE. 6 sider.
  • Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein. 2012. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 sider.
  • Cao, Maria Dung; Döpkens, Mailin; Krishnamachary, Balaji; Vesuna, Farhad; Gadiya, Mayur M.; Lønning, Per Eystein; Bhujwalla, Zaver M.; Gribbestad, Ingrid S; Glunde, Kristine. 2012. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine. 1033-1042.
  • Straume, Anne Hege; Løvås, Kristian; Miletic, Hrvoje; Gravdal, Karsten; Lønning, Per Eystein; Knappskog, Stian. 2012. Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. European Journal of Endocrinology. 941-949.
  • Bjørnslett, Merete Pauline; Knappskog, Stian; Lønning, Per Eystein; Dørum, Anne. 2012. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer. 6 sider.
  • Straume, Anne Hege; Knappskog, Stian; Lønning, Per Eystein. 2012. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology. 69-75.
  • Bliss, Judith M.; Kilburn, Lucy S.; Coleman, Robert E.; Forbes, John F.; Coates, Alan S.; Jones, Stephen E.; Jassem, Jacek; Delozier, Thierry; Andersen, Jørn; Paridaens, Robert; Van de Velde, Cornelis J.H.; Lønning, Per Eystein; Morden, James; Reise, Justine; Cisar, Laura; Menschik, Thomas; Coombes, R. Charles. 2012. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. Journal of Clinical Oncology. 709-717.
  • Schuster, Cornelia; Eikesdal, Hans Petter; Puntervoll, Hanne Eknes; Geisler, Jürgen; Geisler, Stephanie; Heinrich, Daniel; Molven, Anders; Lønning, Per Eystein; Akslen, Lars A.; Straume, Oddbjørn. 2012. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLOS ONE. 8 sider.
  • Lønning, Per Eystein; Haynes, Ben P.; Straume, Anne Hege; Dunbier, Anita; Helle, Hildegunn; Knappskog, Stian; Dowsett, Mitch. 2011. Recent data on intratumor estrogens in breast cancer. Steroids. 786-791.
  • Knappskog, Stian; Myklebust, Line Merethe; Busch, Christian; Aloysius, Thomas Aquinas; Varhaug, Jan Erik; Lønning, Per Eystein; Lillehaug, Johan R.; Pendino, Frederic. 2011. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer(dagger). Annals of Oncology. 2208-2215.
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein. 2011. Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. PLOS ONE. 10 sider.
  • Knappskog, Stian; Lønning, Per Eystein. 2011. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. OncoTarget. 251-258.
  • Fjøsne, Hans Erikssønn; Søreide, Jon Arne; Kåresen, Rolf; Lønning, Per Eystein; Jacobsen, Anne-Birgitte; Lundgren, Steinar. 2011. Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials. Acta Oncologica. 1068-1074.
  • Akslen, Lars A.; Straume, Oddbjørn; Geisler, Stephanie; Sørlie, Therese; Chi, Jen-Tan Ashley; Aas, Turid; Børresen-Dale, Anne-Lise ; Lønning, Per Eystein. 2011. Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 9-12.
  • Knappskog, Stian; Lønning, Per Eystein. 2011. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription.
  • Busch, Christian; Geisler, Jürgen; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. European Journal of Cancer. 2127-2133.
  • Haynes, Ben P.; Straume, Anne Hege; Geisler, Jurgen; A'Hern, Roger; Helle, Hildegunn; Smith, Ian E; Lønning, Per Eystein; Dowsett, Mitch. 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • Geisler, Jurgen; Lønning, Per Eystein. 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • Geisler, Jurgen; Suzuki, Takashi; Helle, Hildegunn; Miki, Yasuhiro; Nagasaki, Shuji; Duong, Nhat Kim; Ekse, Dagfinn; Aas, Turid; Evans, Dean B.; Lønning, Per Eystein; Sasano, Hironobu. 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • Lønning, Per Eystein; Helle, Hildegunn; Duong, Nhat Kim; Ekse, Dagfinn; Aas, T; Geisler, Jurgen. 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • Lønning, Per Eystein. 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • Lønning, Per Eystein. 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • Nordgard, Silje H.; Alnaes, GIG; Hihn, Björn; Lingjærde, Ole Chr.; Liestøl, Knut; Tsalenko, Anya; Sørlie, Therese; Lonning, PE; Børresen-Dale, Anne-Lise; Kristensen, Vessela Nedelcheva. 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
  • Geisler, Jurgen; Helle, Hildegunn; Ekse, D.; Duong, Nhat Kim; Evans, Dean B.; Nordbø, Yngve; Aas, Turid; Lønning, Per Eystein. 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • Rønneberg, Jo Anders; Tost, Jörg; Solvang, Hiroko K.; Alnæs, Grethe Irene Grenaker; Johansen, Fredrik E.; Brendeford, Ellen M.; Yakhini, Zohar; Gut, Ivo G.; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Gabrielsen, Odd Stokke; Kristensen, Vessela Nedelcheva. 2008. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 5562-5571.
  • Norum, Jan; Olsen, Jan Abel; Wist, Erik; Lonning, PE. 2007. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
  • Geisler, Jurgen; Haynes, Ben; Ekse, Dagfinn; Dowsett, Mitch; Lønning, Per Eystein. 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • Coombes, R. Charles; Kilburn, Lucy S.; Snowdon, Claire F.; Paridaens, Robert; Coleman, Ronert E.; Jones, Stephen E.; Jassem, Jacek; Van de Velde, Cornelis J.H.; Delozier, Thierry; Álvarez , Inmaculada; Del Mastro, Lucia; Ortmann, Olaf; Diedrich, Klaus; Coates, Alan S.; Bajetta, Emilio; Holmberg, Stig B.; Dodwell, David; Mickiewicz, Elizabeth; Andersen, Jesper; Lønning, Per Eystein; Cocconi, Giorgio; Forbes, John; Castiglione, Monica; Stuart, Nick; Stewart, Alan; Fallowfield, Lesley J.; Bertelli, Gian; Hall, Emma; Bogle, Richard G.; Carpentieri, Mary; Colajori, Elena; Subar, Milayna; Ireland, Elizabeth; Bliss, Judith M. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • Grudic, Amra; Jul-Larsen, Åsne; Haring, Stuart J.; Wold, Marc S.; Lønning, Per Eystein; Bjerkvig, Rolf; Bøe, Stig Ove. 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • Grudic, Amra; Jul-Larsen, Åsne; Haring, SJ; Wold, MS; Lønning, Per Eystein; Bjerkvig, Rolf; Bøe, Stig Ove. 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • Knappskog, Stian; Chrisanthar, Ranjan; Staalesen, Vidar; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Lillehaug, Johan Richard; Lønning, Per Eystein. 2007. Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
  • Lønning, Per Eystein. 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • Lønning, Per Eystein; Geisler, Jurgen. 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
  • Lønning, Per Eystein. 2007. Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
  • Nordgard, Silje H.; Ritchie, Marylyn D.; Jensrud, Sigrid D.; Motsinger, Alison A.; Alnaes, GIG; Lernmon, Gordon; Berg, Marianne; Gelsler, S; Moore, Jason H.; Lonning, PE; Børresen-Dale, Anne-Lise; Kristensen, Vessela Nedelcheva. 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • Monstad, Sissel Evy; Storstein, Anette Margrethe; Dørum, Anne; Knudsen, Anette; Lønning, Per Eystein; Salvesen, Helga; Aarseth, Jan Harald; Vedeler, Christian A. 2006. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
  • Staalesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan; Nordgard, Silje H.; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Gram, Inger Torhild; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Lillehaug, Johan Richard; Lønning, Per Eystein. 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • Knudsen, Anette; Monstad, Sissel Evy; Dørum, Anne; Lønning, Per Eystein; Salvesen, Helga; Drivsholm, Lars; Aarseth, Jan Harald; Vedeler, Christian A. 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 1280-1284.
  • Bøe, Stig Ove; Haave, Marte; Jul-Larsen, Åsne; Grudic, Amra; Bjerkvig, Rolf; Lønning, Per Eystein. 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
  • Sørlie, Therese; Perou, Charles M.; Fan, Cheng; Geisler, Stephanie; Aas, Turid; Nobel, Andrew; Anker, Gun; Akslen, Lars A.; Botstein, David; Børresen-Dale, Anne-Lise; Lønning, Per Eystein. 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • Baumbusch, Lars Oliver; Myhre, Simen; Langerød, Anita; Bergamaschi, Anna; Geisler, Stephanie B; Lønning, Per Eystein; Deppert, Wolfgang; Dornreiter, Irene; Børresen-Dale, Anne-Lise. 2006. Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 47.
  • Muggerud, Aslaug Aamodt; Johnsen, Hilde; Barnes, Debra A.; Steel, Adam; Lønning, Per Eystein; Lonning, PE; Sørlie, Therese; Naume, Bjørn; Børresen-Dale, Anne-Lise. 2006. Evaluation of MetriGenix custom 4D (TM) arrays applied for detection of breast cancer subtypes. BMC Cancer. 6 sider.
  • Lønning, Per Eystein. 2006. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology. 217-225.
  • Lønning, Per Eystein; Geisler, Jürgen. 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • Geisler, J; Lønning, Per Eystein; Krag, LE; Løkkevik, Erik; Risberg, Terje; Hagen, AI; Schlichting, E; Lien, EA; Øfjord, Erik S.; Eide, GE; Di Salle, Enrico; di Salle, E; Paolini, J. 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Thorsen, Frits Alan; Afione, Sandra; Huszthy, Peter Csaba; Tysnes, Berit Bølge; Svendsen, Agnete; Bjerkvig, Rolf; Kotin, Robert M.; Lønning, Per Eystein; Hoover, Frank. 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
  • Knappskog, Stian; Geisler, Jürgen; Arnesen, Thomas; Lillehaug, Johan; Lønning, Per Eystein. 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • Aas, Turid; Geisler, Stephanie; Helle, Hildegunn; Børresen-Dale, Anne-Lise ; Lønning, Per Eystein; Akslen, Lars Andreas. 2005. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncology Reports. 525-530.
  • Jeffrey, SS; Lønning, Per Eystein; Hillner, BE. 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • Lønning, Per Eystein; Sørlie, T; Børresen-Dale, Anne-Lise. 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • Kristensen, Vessela Nedelcheva ; Sørlie, Therese; Geisler, E; Yoshimura, Noriko; Lingjærde, Ole Christian; Glad, Ingrid; Frigessi, Arnoldo ; Harada, Nobuhiro; Lonning, PE; Børresen-Dale, Anne-Lise. 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
  • Lønning, Per Eystein. 2005. Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 723-728.
  • Joensuu, Heikki; Ejlertsen, Bent; Lønning, Per Eystein; Rutqvist, Lars-Erik. 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • Lønning, Per Eystein; Geisler, Jürgen. 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • Lønning, Per Eystein. 2004. Understanding chemoresistance- the ultimate challenge in cancer therapy. Breast Cancer Online.
  • Lønning, Per Eystein. 2004. Oestrogen suppression; lessons from clinical studies. Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism. 33-45.
  • Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, X; Langerød, A; Kåresen, Rolf; OH, DS; Dressler, LG; Lønning, Per Eystein; Strausberg, RL; Chanock, S; Børresen-Dale, Anne-Lise; Perou, CM. 2004. Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • Usary, Jerry; Llaca, Victor; Karaca, Gamze; Presswala, Shafaq; Karaca, Mehmet; He, Xiaping; Langerød, Anita; Kåresen, Rolf; Oh, Daniel S; Dressler, Lynn G; Lønning, Per Eystein; Strausberg, Robert l; Chanock, Stephen; Børresen-Dale, Anne-Lise ; Perou, Charles M. 2004. Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • Staalesen, Vidar; Leirvaag, B.; Lillehaug, Johan; Lønning, Per Eystein. 2004. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clinical Cancer Research. 3438-3443.
  • Lønning, Per Eystein. 2004. Genes causing inherited cancer as beacons to identify the mechanism of chemoresistance. Trends in Molecular Medicine. 113-118.
  • Coombes, R. Charles; Hall, Emma; Gibson, Lorna J.; Paridaens, Robert; Jassem, J; Delozier, T; Jones, S; Alvarez, I; Bertelli, G; Ortman, O; Coates, AS; Bajetta, E; Dodwell, D; Coleman, RE; Fallowfield, LJ; Mickiewicz, E; Andersen, J; Lønning, Per Eystein; Coocconi, C; Stewart, A; Stuart, N; Snowdon, CF; Carpentieri, M; Massimini, G; Bliss, JM. 2004. Exemestane improves disease-free survival in postmenopausal patients with early breast cancer after two to three years of tamoxifen: a double blind study. New England Journal of Medicine. 1081-1092.
  • Troester, MA; Hoadley, KA; Sørlie, T; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Herbert, B-S; Jerry, W; Shay, JW; Perou, CM. 2004. Cell-type specific responses to chemotherapeutics in breast cancer. Cancer Research. 4218-4226.
  • Staalesen, Vidar; Falck, J.; Geisler, Stephanie; Bartkova, J.; Børresen-Dale, A.L.; Lukas, J.; Lillehaug, Johan; Bartek, J; Lønning, Per Eystein. 2004. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene. 8535-8544.
  • Staalesen, Vidar; Falck, Jacob; Geisler, Stephanie; Bartkova, Jirina; Børresen-Dale, Anne-Lise ; Lukas, Jiri; Lillehaug, Johan Richard; Bartek, Jiri; Lønning, Per Eystein. 2004. Alternative splicing and mutation status of CHEK2 in stag III breast cancer. Oncogene. 8535-8544.
  • Lien, Ernst Asbjørn; Lønning, Per Eystein. 2000. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Laake, K.; Vu, P.; Andersen, T.I.; Erikstein, Bjørn; Kåresen, Rolf; Lønning, Per Eystein; Skovlund, E.; Børresen-Dale, Anne-Lise. 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • Lønning, Per Eystein. 2000. Pharmacology and clinical experience with exemestane. Experimental Opinion Investigation Drugs. 1897-1905.
  • Perou, C.M.; Sørlie, T.; van de Rijn, M.; Jeffrey, S.S.; Pollack, J.R.; Johnsen, Hilde; Geisler, Stephanie; Aass, Turid; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Brown, P.O.; Botstein, D. 2000. Molecular portraits of human breast tumours. Nature. 747-752.
  • Lønning, Per Eystein. 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • Lønning, Per Eystein. 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • Lønning, Per Eystein; Bajetta, E.; Murray, R.; Tubiana-Hulin, M.; Eisenberg, P.D.; Massimini, G.; Celio, L; Pitt, P.; Fowst, C.; Arkhipov, A.; Di Salle, E.; Polli, A. 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • Geisler, Jürgen; Berntsen, Hildegunn; Lønning, Per Eystein. 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Lønning, Per Eystein; Johnsen, H; Geisler, Stephanie; Aas, T; Smith-Sørensen, B; Akslen, Lars A.; Børresen-Dale, AL. 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • Lønning, Per Eystein; Johnsen, H; Geisler, Stephanie; Aas, T; Smith-Sørensen, B; Akslen, A; Børresen-Dale, AL. 1999. TP53 as a predictor of response to chemotherapy in breast cancer. Review. European School of Oncology Scientific Updates. 73-88.
  • Lønning, Per Eystein; Johnsen, H; Geisler, Stephanie; Aas, Turid; Smith-Sørensen, B; Akslen, Lars A.; Børresen-Dale, AL. 1999. TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • Love, RR; Anker, Gun Birgitta; Yang, Y; Refsum, Helga; Ueland, Per Magne; Lønning, Per Eystein; Lien, Ernst Asbjørn. 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Love, RR; Anker, Gun Birgitta; Yang, Y; Refsum, Helga; Ueland, Per Magne; Lønning, Per Eystein. 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Diamandis, EP; Helle, Svein Inge; Yu, H; Melegos, DN; Lundgren, S; Lønning, Per Eystein. 1999. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer. 891-898.
  • Geisler, Jürgen; Ormsjø, I; Helle, Svein Inge; Ekse, Dagfinn; Silsand, T; Lønning, Per Eystein. 1999. Plasma estrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. Endocrinology. 265-270.
  • Anker, Gun Birgitta; Refsum, Helga; Ueland, Per Magne; Johannessen, Dag Clement; Lien, Ernst Asbjørn; Lønning, Per Eystein. 1999. Influence of aromatase inhibitors on plasma total homocysteine levels in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Anker, Gun Birgitta; Refsum, Helga; Ueland, Per Magne; Johannessen, Dag Clement; Lien, Ernst Asbjørn; Lønning, Per Eystein. 1999. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Geisler, Stephanie; Lønning, Per Eystein; Aas, T; Johnsen, H; Fluge, Ø; Haugen, Dagny R. Faksvåg; Lillehaug, Johan; Akslen, Lars A.; Børresen-Dale, AL. 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • Helle, Svein Inge; Lundgren, S; Geisler, Stephanie; Ekse, Dagfinn; Holly, Jeff M.P.; Lønning, Per Eystein. 1999. Effect of treatment with megestrol acetate on the IGF-system: Time and dose dependency. European Journal of Cancer. 1070-1075.
  • Lønning, Per Eystein. 1999. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocrine-Related Cancer. 251-257.
  • Kristensen, VN; Haraldsen, EK; Anderson, KB; Lønning, Per Eystein; Erikstein, B; Kåresen, R; Gabrielsen, OS; Børresen-Dale, AL. 1999. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to SP-1. Cancer Research. 2825-2828.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Aakvaag, Asbjørn; Lien, Ernst Asbjørn. 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Aakvaag, Asbjørn; Lien, Ernst Asbjørn. 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Anker, Gun Birgitta; Aakvaag, Asbjørn; Lønning, Per Eystein; Lien, Ernst Asbjørn. 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Lønning, Per Eystein. 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • Lønning, Per Eystein; Geisler, Jürgen; Dowsett, Mitch. 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • Helle, Svein Inge; Geisler, Jürgen; Poulsen, J.P.; Hestdal, K.; Meadows, K.A.; Collins, W.; Tveit, K.M.; Viste, Asgaut; Holly, Jeff M.P.; Lønning, Per Eystein. 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • Helle, S.I.; Geisler, J.; Poulsen, J. P.; Hestad, Kjetil; Meadows, K.; Collins, W.; Tveit, Magne Kjell; Viste, A.; Holly, J.M.P.; Lønning, Per Eystein. 1998. Microencapsulated Octreotide in Advanced Gastrointestinal and Pancreatic Cancer: a Phase I Study. British Journal of Cancer. 14-20.
  • Guttormsen, Anne Berit; Ueland, Per Magne; Lønning, Per Eystein; Mella, Olav; Refsum, Helga. 1998. Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
  • Guttormsen, Anne Berit; Ueland, Per Magne; Lønning, Per Eystein; Mella, O.; Refsum, Helga. 1998. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Guttormsen, Anne Berit; Ueland, Per Magne; Lønning, Per Eystein; Mella, Olav; Refsum, Helga. 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Helle, Svein Inge; Jonat, W.; Giurescu, M.; Ekse, Dagfinn; Holly, Jeff M.P.; Lønning, Per Eystein. 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • Berntsen, Hildegunn; Ekse, Dagfinn; Netteland, Bjørn; Berge, Rolf Kristian; Svardal, Asbjørn; Johannessen, Dag Clement; Lønning, Per Eystein. 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • Haarstad, H.; Lønning, Per Eystein; Gundersen, S.; Wist, E.; Raabe, N.; Kvinnsland, Steinar. 1998. Influence of droloxifene on metastatic breast cancer as first line endocrine treatment. Acta Oncologica. 365-368.
  • Geisler, Jürgen; Lundgren, S.; Berntsen, Hildegunn; Greaves, J.L.; Lønning, Per Eystein. 1998. Influence of dexaminoglutethimide, optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patie. Journal of Clinical Endocrinology and Metabolism. 2687-2693.
  • Geisler, Jürgen; King, N.; Anker, Gun Birgitta; Ornati, G.; Di Salle, E.; Lønning, Per Eystein. 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • Geisler, Jürgen; Geisler, Stephanie; Lønning, Per Eystein; Småland, Rune; Tveit, K. M.; Refsum, Helga; Ueland, Per Magne. 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Geisler, Jürgen; Geisler, Stephanie; Lønning, Per Eystein; Småland, Rune; Tveit, Kjell Magne; Refsum, Helga; Ueland, Per Magne. 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Lønning, Per Eystein. 1998. Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. British Journal of Cancer. 12-15.
  • Helle, Svein Inge; Anker, Gun Birgitta; Meadows, K.A.; Holly, Jeff M.P.; Lønning, Per Eystein. 1998. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas. 259-265.
  • Børresen-Dale, Anne-Lise; Smith-Sørensen, Birgitte; Aas, Turid; Johnsen, Hilde; Geisler, S.; Kærn, Janne; Trope, Claes Gøran; Lønning, Per Eystein. 1997. Subgroups of TP53 mutations may predict clinical behaviour and therapy response in breast and ovary cancer patients. Breast and Ovarian Cancer: Molecular Markers of Risk: Progression and new Therapeutic strategies, Pisa, Italy..
  • Lien, Ernst Asbjørn; Anker, Gun Birgutta; Lønning, Per Eystein; Refsum, Helga; Ueland, Per Magne. 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Geisler, Jürgen; Engelsen, Bernt; Geisler, Stephanie; Lønning, Per Eystein. 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Paulsen, Trond H; Aas, Turid; Børresen, Anne-Lise; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Paulsen, Trond H; Aas, Turid; Børresen, A-L; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Ellis, P. A.; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Aas, Turid; Geisler, S.; Akslen, Lars A.; Salter, J.; Smith, I. E.; Dowsett, M. 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Aas, T; Børresen, A-L; Geisler, D; Smidth-Sørensen, B; Johnsen, H; Varhaug, Jan Erik; Akslen, Lars A.; Lønning, Per Eystein. 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Aas, Turid; Geisler, Stephanie; Paulsen, Trond H; Børresen, AL; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Aas, Turid; Geisler, Stephanie; Paulsen, Trond H; Børresen, Anne-Lise; Varhaug, Jan Erik; Lønning, Per Eystein; Akslen, Lars A. 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Helle, Svein Inge; Lønning, Per Eystein. 1996. Insulin-like growth factors in breast cancer. Acta Oncologica. 19-22.
  • Helle, Svein Inge; Omsjø, I. H.; Hughes, S. C. Cwyfan; Botta, L.; Hüls, G.; Holly, Jeff M.P.; Lønning, Per Eystein. 1996. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clinical Endocrinology. 727-732.
  • Lønning, Per Eystein. 1996. Aromatase inhibition for breast cancer treatment. Acta Oncologica. 38-43.
  • Lønning, Per Eystein; Helle, Svein Inge; Johannessen, Dag Clement; Adlercreutz, Herman; Lien, Ernst Asbjørn; Tally, M; Eske, Dagfinn; Fotsis, T; Anker, Gun Birgitta; Hall, K. 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne; Refsum, Helga; Lien, Ernst Asbjørn. 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne; Refsum, Helga; Lien, Ernst Asbjørn. 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Engan, T; Krane, J; Johannessen, Dag Clement; Lønning, Per Eystein; Kvinnsland, Stener. 1995. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Research and Treatment. 287-297.
  • Lønning, Per Eystein; Helle, Svein Inge; Johannesen, Dag Clement; Adlercreutz, Herman; Lien, Ernst Asbjørn; Tally, M.; Ekse, Dagfinn; Fotsis, T.; Anker, Gun Birgitta; Hall, K.J. 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Lien, Ernst Asbjørn; Anker, Gun Birgitta; Lønning, Per Eystein; Ueland, Per Magne. 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Lønning, Per Eystein; Helle, Svein Inge; Frost, VJ; Holly, Jeff M.P.; Hall, K. 1995. Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
  • Rubens, R. D.; Bajetta, E.; Bonneterre, J.; Klijn, J. G. M.; Lønning, Per Eystein; Paridaens, R. 1994. Treatment of relapse of breast cancer after adjuvant systemic therapy - review and guidelines for future research. European Journal of Cancer. 106-111.
  • Corry, J. F.; Lønning, Per Eystein. 1994. Systemic therapy in breast cancer: Efficacy and cost utility. Pharm Econ. 198-212.
  • Aas, T.; Varhaug, Jan Erik; Kolnes, J.; Søreide, Jon Arne; Lønning, Per Eystein. 1994. Primærbehandling av lokalavansert brystkreft med bruk av neoadjuvant kjemoterapi. Tidsskrift for Den norske legeforening. 668-670.
  • Lønning, Per Eystein; Lien, Ernst Asbjørn. 1994. Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • MacNeill, F. A.; Jacobs, S.; Lønning, Per Eystein; Powels, T. J.; Dowsett, M. 1994. Combined treatment with 4-hydroxyandrostendione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. British Journal of Cancer. 1171-1175.
  • Lønning, Per Eystein. 1993. Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews. 65-77.
  • Johannessen, Dag Clement; Adlercreutz, Herman; Fotsis, T.; Lønning, Per Eystein. 1993. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
  • Lønning, Per Eystein; Lien, E. 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Lønning, Per Eystein; Lien, E. 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Lønning, Per Eystein. 1993. Dose response evaluation - Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics. 1-5.
  • Poon, G. K.; Chui, Y. C.; McCague, R.; Lønning, Per Eystein; Feng, R.; Rowlands, M. G.; Jarman, M. 1993. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
  • Jones, A. L.; MacNeil, F.; Jacobs, S.; Lønning, Per Eystein; Powles, T. J.; Dowsett, M. 1992. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aramotisation in breast cancer patients. European Journal of Cancer. 1712-1716.
  • MacNeil, F. A.; Jones, A. L.; Jacobs, S.; Lønning, Per Eystein; Powles, T. J.; Dowsett, M. 1992. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer. 692-697.
  • Reed, W.; Gundersen, S.; Lønning, Per Eystein; Nesland, J. 1992. Prognostiske parametre ved lokalisert brystkreft. Prognostic parameters in early breast cancer. Tidsskrift for Den norske legeforening. 757-759.
  • Lien, Ernst Asbjørn; Johannessen, Dag Clement; Aakvaag, A.; Lønning, Per Eystein. 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Lien, Ernst Asbjørn; Johannesen, D. C.; Aakvaag, A.; Lønning, Per Eystein. 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Lien, Ernst Asbjørn; Johannessen, Dag Clement; Aakvaag, A.; Lønning, Per Eystein. 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Lien, Ernst Asbjørn; Johannessen, Dag Clement; Aakvaag, A.; Lønning, Per Eystein. 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Lønning, Per Eystein; Hall, K.; Aakvaag, A.; Lien, Ernst Asbjørn. 1992. Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Lønning, Per Eystein; Hall, K.; Aakvaag, A.; Lien, Ernst Asbjørn. 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Lønning, Per Eystein; Lien, E.; Lundgren, S.; Kvinnsland, Steinar. 1992. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Lønning, Per Eystein; Wiedemann, G.; Gmelin, E.; Thor-Wiedemann, S.; Wirsching, J. 1991. Wie wirkungsvoll ist das Mammographie-Screening? Deutsche Medizinische Wochenschrift. 108-112.
  • Lønning, Per Eystein. 1991. Treatment of early breast cancer with conservation of the breast. Acta Oncologica. 779-792.
  • Lønning, Per Eystein; Jacobs, S.; Jones, A.; Haynes, B.; Powles, T. J.; Dowsett, M. 1991. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer. 789-793.
  • Jacobs, S.; Lønning, Per Eystein; Haynes, B.; Griggs, L.; Dowsett, M. 1991. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of enzyme inhibition (Print). 315-325.
  • Lønning, Per Eystein; Wiedemann, G. 1991. Leser-Zuschriften - Mammographie-Screening. Deutsche Medizinische Wochenschrift. 636-637.
  • Lien, Ernst Asbjørn; Wester, Knut; Lønning, Per Eystein; Solheim, E.; Ueland, P. M. 1991. Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Lien, Ernst Asbjørn; Wester, Knut; Lønning, Per Eystein; Solheim, E.; Ueland, P. M. 1991. Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
  • Lundgren, S.; Lønning, Per Eystein. 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
  • Lundgren, S.; Lønning, Per Eystein; Utaaker, E.; Aakvaag, A.; Kvinnsland, S. 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
  • Lien, Ernst Asbjørn; Anker, Gun Birgitta; Lønning, Per Eystein; Solheim, E.; Ueland, Per Magne. 1990. Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Vitenskapelig foredrag
  • Cao, Maria Dung; Giskeødegård, Guro F.; Bathen, Tone Frost; Sitter, Beathe; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • Cao, Maria Dung; Jiang, Lu; Krishnamachary, Balaji; Doepkens, Mailin; Vesuna, Farhad; Lønning, Per Eystein; Bhjuwalla, Zaver M.; Gribbestad, Ingrid S; Glunde, Kristine. 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • Cao, Maria Dung; Sitter, Beathe; Bathen, Tone Frost; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • Cao, Maria Dung; Sitter, Beathe; Bathen, Tone Frost; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • Geisler, Jürgen; Berntsen, Hildegunn; Ottestad, L; Lindtjørn, Bernt; Dowsett, Mitch; Lønning, Per Eystein. 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • Geisler, Jürgen; Berntsen, Hildegunn; Ottestad, J; Lindtjørn, Bernt; Dowsett, Mitch; Lønning, Per Eystein. 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • Geisler, Jürgen; Lønning, Per Eystein; Dowsett, M.; King, N.; Lundgren, L.; Ottestad, L.; Kormeset, P. O.; Walton, P. L. 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • Johannessen, Dag Clement; Engan, T.; Kvinnsland, S.; Lønning, Per Eystein. 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • Helle, Svein Inge; Frost, V. J.; Holly, Jeff M.P.; Lønning, Per Eystein. 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Vitenskapelig antologi/Konferanseserie
  • Sørlie, Therese; Børresen-Dale, Anne-Lise ; Lønning, Per Eystein; Brown, P. O; Botstein, David. 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Sammendrag/abstract
  • Lønning, Per Eystein. 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • Hans, Volkmar; Evans, Dean B.; Lønning, Per Eystein; Geisler, Jurgen. 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • Haynes, B; Straume, Anne Hege; Geisler, Jurgen; Ahern, R; Lonning, PE; Dowsett, M. 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • Lønning, Per Eystein. 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • Lønning, Per Eystein. 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • Gjerde, Jennifer Fernandez; Geisler, Jurgen; Lundgren, Steinar; Ekse, Dagfinn; Breilid, Harald; Hauglid, M; Varhaug, EJ; Steen, Vidar Martin; Lonning, PE; Lien, Ernst Asbjørn. 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Busch, Christian; Geisler, Jurgen; Lillehaug, Johan R.; Lønning, Per Eystein. 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • Lønning, Per Eystein. 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • Gjerde, Jennifer Fernandez; Geisler, Jurgen; Lundgren, Steinar; Ekse, Dagfinn; Breilid, Harald; Hauglid, Marianne; Varhaug, Jan Erik; Mellgren, Gunnar; Steen, Vidar Martin; Lønning, Per Eystein; Lien, Ernst Asbjørn. 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Staalesen, Vidar; Knappskog, Stian; Geisler, Stephanie; Baumbusch, L; Børresen-Dale, Anne-Lise; Lillehaug, Johan; Lønning, Per Eystein; Lonning, PE. 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Vitenskapelig oversiktsartikkel/review
  • Dowsett, Mitch; Lønning, Per Eystein; Davidson, Nancy E. 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. 1580-1583.
  • Lønning, Per Eystein. 2015. Estradiol measurement in translational studies of breast cancer. 26-31.
  • Austreid, Eilin; Lønning, Per Eystein; Eikesdal, Hans Petter. 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 681-700.
  • Lønning, Per Eystein; Knappskog, Stian. 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. 5315-5330.
  • Lønning, Per Eystein; Eikesdal, Hans Petter. 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. R183-R201.
  • Knappskog, Stian; Lønning, Per Eystein. 2012. P53 and its molecular basis to chemoresistance in breast cancer. S23-S30.
  • Lønning, Per Eystein. 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. 503-514.
  • Lønning, Per Eystein; Haynes, Ben P.; Straume, Anne Hege; Dunbier, Anita; Helle, Hildegunn; Knappskog, Stian; Dowsett, Mitch. 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. 4948-4958.
  • Mouridsen, Henning T; Lønning, Per Eystein; Beckmann, Matthias W; Blackwell, Karen; Doughty, Julie; Gligorov, Joseph; Llombart-Cussac, Antonio; Robidoux, Andre; Thurlimann, Beat; Gnant, Michael. 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. 1825-1836.
  • Lønning, Per Eystein. 2010. Molecular basis for therapy resistance. 284-300.
  • Lønning, Per Eystein. 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? 527-535.
  • Christoffersen, Thoralf; Guren, Tormod K.; Spindler, Karen-Lise Garm; Dahl, Olav; Lønning, Per Eystein; Gjertsen, Bjørn Tore. 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • Lønning, Per Eystein. 2009. Additive endocrine therapy for advanced breast cancer - back to the future. 1092-1101.
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Indications and limitations of third-gene ration aromatase inhibitors. 723-739.
  • Lønning, Per Eystein; Knappskog, Stian; Staalesen, Vidar; Chrisanthar, Ranjan; Lillehaug, Johan. 2007. Breast cancer prognostication and prediction in the postgenomic era. 1293-1306.
  • Geisler, Jürgen; Lønning, Per Eystein. 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. 53-61.
  • Lønning, Per Eystein. 2004. Aromatase inhibitors in breast cancer. 179-189.

Se fullstendig oversikt over publikasjoner i CRIStin.

Kompetansefelt